Pomerantz Investigates SELLAS Life Sciences Group for Securities Fraud
Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. concerning potential securities fraud. The probe focuses on alleged delays in the company's clinical trial results for Galinpepimut-S (GPS).
Pomerantz LLP, a law firm specializing in securities litigation, has initiated an investigation into SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) and its officers and/or directors. The probe will determine if the company and its leadership have engaged in securities fraud or other unlawful business practices.
The investigation was prompted by a news report on August 28, 2026, stating that the company's Phase 3 clinical trial for its drug Galinpepimut-S (GPS) had reached a pre-specified endpoint of 80 patient deaths, an event expected to trigger the release of trial results. However, as of that report, SELLAS had not yet published the findings.
Following this news, SELLAS's stock price fell by $2.00 per share, or 13.15%, to close at $13.21 on August 28, 2026. Pomerantz is advising investors who have suffered losses to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Pomerantz LLP is a globally recognized law firm with extensive experience in corporate and securities litigation, known for recovering substantial damages for its clients in class-action lawsuits.